Swiss drug major Novartis (NVS) said Wednesday that a new analysis of the Phase III EXPAND study showed that treatment with Mayzent (siponimod) had a clinically meaningful positive impact on cognitive processing speed or CPS in patients living with secondary progressive multiple sclerosis or SPMS. Cognitive processing speed is an important element in cognitive function.
from RTT - Biotech http://bit.ly/3041Y6H
via IFTTT
No comments:
Post a Comment